Prim SA
F:5P1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (11.9), the stock would be worth €15.98 (22% upside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 9.7 | €13.05 |
0%
|
| 3-Year Average | 11.9 | €15.98 |
+22%
|
| 5-Year Average | 11.4 | €15.37 |
+18%
|
| Industry Average | 10.7 | €14.36 |
+10%
|
| Country Average | 12.6 | €17.01 |
+30%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
€209.2m
|
/ |
Jan 2026
€22m
|
= |
|
|
€209.2m
|
/ |
Dec 2026
€25.3m
|
= |
|
|
€209.2m
|
/ |
Dec 2027
€28.3m
|
= |
|
|
€209.2m
|
/ |
Dec 2028
€31.8m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| ES |
|
Prim SA
F:5P1
|
226.3m EUR | 9.7 | 13.6 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
159.2B USD | 19 | 25.4 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.7B USD | 56.1 | 60.1 | |
| US |
|
Stryker Corp
NYSE:SYK
|
126B USD | 24 | 38.8 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.8B USD | 18.8 | 23.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
96.2B USD | 26.4 | 33.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
41.6B EUR | 15.6 | 19.7 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.3B USD | 26.3 | 44.1 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
46.1B USD | 34 | 43.5 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
44.3B USD | 16.9 | 25.2 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
32.5B USD | 13.6 | 15.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 8.1 |
| Median | 12.6 |
| 70th Percentile | 17 |
| Max | 700.4 |
Other Multiples
Prim SA
Glance View
Prim SA engages in the health sector business. The company is headquartered in Mostoles, Madrid. The Company’s products portfolio comprises implantable orthopedic products, silicone foot products, abduction splints, mastectomy lingerie, prosthetic components, as well as articulated electric beds and various types of accessories for geriatric centers. Through its subsidiary Inmobiliaria Catharsis SA, the Company is also active in the Real State sector. Prim SA is a parent of Grupo Prim, a group which comprises such a number of controlled entities as Enraf Nonius Iberica SA, Establecimientos Ortopedicos Prim SA, and Luga Suministros Medicos SL, among others.
